Scottish biotech firm Omega Diagnostics has said it is not aware of “any material reason” for a further surge in the company’s share price.
The value of the AIM-listed company rose more than 18% in trading on Wednesday after Sky News aired a report that referred to Omega’s part in the UK Rapid Test Consortium, which is working to develop at-home tests to detect coronavirus antibodies. It is also involved in a second partnership with Bedfordshire-based Mologic to develop a laboratory test for Covid-19 antibodies.
READ MORE: Omega Diagnostics surges as virus testing plans progress
“In respect of both these opportunities the company will keep the market informed as matters develop,” Omega said in a statement.
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.